TFX trades 27.5% below Wall Street's consensus target of $155.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TFX achieves its forward estimates and maintains a stable P/E multiple of 16.9x. This scenario reflects the blended consensus of 29 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Teleflex Incorporated (TFX) has a Wall Street consensus price target of $155.25, based on estimates from 29 covering analysts. With the stock currently trading at $121.75, this represents a potential upside of +27.5%. The company has a market capitalization of $5.39B.
Analyst price targets range from a low of $140.00 to a high of $170.00, representing a 19% spread in expectations. The median target of $156.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 15 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TFX trades at a trailing P/E of -6.0x and forward P/E of 16.9x. Analysts expect EPS to grow +130.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ICUSeaStar Medical Holding Corporation | $14M | $3.53 | $8.00 | +126.6% | Buy | — | 1 |
 UTMDUtah Medical Products, Inc. | $239M | $75.01 | — | — | — | 11.9x | — |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ANGOAngioDynamics, Inc. | $641M | $15.51 | $19.50 | +25.7% | Hold | — | 11 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.07 | $101.88 | +17.0% | Buy | 20.2x | 15 |
 BDXBecton, Dickinson and Company | $50.3B | $182.52 | $186.88 | +2.4% | Hold | 14.4x | 34 |
 BAXBaxter International Inc. | $12.1B | $23.49 | $25.00 | +6.4% | Hold | 11.4x | 36 |
 MDTMedtronic plc | $114.7B | $89.30 | $98.00 | +9.7% | Buy | 14.9x | 51 |
 BSXBoston Scientific Corporation | $66.3B | $44.62 | $66.30 | +48.6% | Buy | 13.6x | 44 |
Quick answers to the most common questions about buying TFX stock.
The consensus Wall Street price target for TFX is $155.25, representing 27.5% upside from the current price of $121.75. With 29 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TFX has a consensus rating of "Buy" based on 29 Wall Street analysts. The rating breakdown is predominantly bullish, with 15 Buy/Strong Buy ratings. The consensus 12-month price target of $155.25 implies 27.5% upside from current levels.
With a forward P/E of 16.8992x, TFX trades at a relatively low valuation. The consensus target of $155.25 implies 27.5% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $170 for TFX, while the most conservative target is $140. The consensus of $155.25 represents the median expectation. These targets typically reflect 12-month expectations.
TFX is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 13 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TFX stock forecast based on 29 Wall Street analysts shows a consensus price target of $155.25, with estimates ranging from $140 (bear case) to $170 (bull case). The median consensus rating is "Buy".
TFX trades at a forward P/E ratio of 16.9x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on TFX, with a "Buy" consensus rating and $155.25 price target (27.5% upside). 15 of 29 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TFX analyst price targets range from $140 to $170, a 19% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $155.25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.